U.S. Firms Delay Cutting China Ties Ahead of Biosecure Act

(Bloomberg) — Few life sciences companies have taken steps to sever ties with firms named in proposed U.S. legislation aimed at cutting reliance on China’s drug supply chain, a survey showed, underscoring lingering uncertainty around the bill.

Although one in four companies are expecting to break their link with those named, which include BGI, MGI Tech Co. Ltd., WuXi AppTec Co. Ltd., a poll conducted by Boston-based L.E.K. Consulting in June found only one in fifty had actually severed ties, and one in ten reported no impact on their partnership decisions.